Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: Initial evidence from the RESPOND study

Matti Aapro, Joanna Van Erps, Karen MacDonald, Pierre Soubeyran, Michael Muenzberg, Matthew Turner, Hans Warrinnier, Tara Albrecht, Ivo L Abraham

Research output: Contribution to journalArticle

17 Scopus citations


Purpose: To model the relationship between scores for practicing in congruence (CSs; 0-10) with EORTC guidelines for erythropoietic proteins (EPs) and haemoglobin (Hb) outcomes observed in the validation study of the RESPOND system. Methods: Thirty four patient pairs matched on cancer type and chemotherapy in pre- (retrospective; clinicians not using RESPOND) and post-cohorts (prospective; clinicians using RESPOND) followed over 4 months following EP treatment initiation. CSs quantify the extent that care was guideline-adherent. Linear and logistic regressions controlling for cohort examined Hb outcomes as a function of CSs. Results: A one-point increase in CS was associated with 0.60 g/dL increase in Hb at month 4 (R2 = 0.40) and 0.56 g/dL increase in Hb change from month 1-4 (R2 = 0.33). Each one-point increase in CS increased the odds of reaching Hb ≥ 11 g/dL by 3.14 (R2 = 0.42) and Hb ≥ 12 g/dL by 2.77 (R2 = 0.45). Conclusion: Guideline-adherent EP treatment may improve Hb outcomes but specifically designed outcomes studies are necessary.

Original languageEnglish (US)
Pages (from-to)8-11
Number of pages4
JournalEuropean Journal of Cancer
Issue number1
Publication statusPublished - Jan 2009



  • Anaemia
  • Erythropoietin
  • Evidence-based practice guidelines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this